Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis by Lorente, L. (Leonardo) et al.
Available online http://ccforum.com/content/13/5/R158Open AccessVol 13 No 5Research
Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix 
metalloproteinases-1 blood levels as biomarkers of severity and 
mortality in sepsis
Leonardo Lorente1, María M Martín2, Lorenzo Labarta3, César Díaz4, Jordi Solé-Violán5, 
José Blanquer6, Josune Orbe7, José A Rodríguez7, Alejandro Jiménez8, Juan M Borreguero-León9, 
Felipe Belmonte2, Juan C Medina2, Maria C LLimiñana10, José M Ferrer-Agüero5, José Ferreres6, 
María L Mora1, Santiago Lubillo2, Manuel Sánchez4, Ysamar Barrios8, Antonio Sierra11 and 
José A Páramo7
1Intensive Care Unit, Hospital Universitario de Canarias, Ofra, s/n. La Laguna, 38320, Santa Cruz de Tenerife, Spain
2Intensive Care Unit, Hospital Universitario Nuestra Señora de Candelaria, Crta del Rosario s/n. Santa Cruz de Tenerife, 38010, Spain
3Intensive Care Unit, Hospital San Jorge de Huesca, Avenida Martínez de Velasco no. 36, Huesca, 22004, Spain
4Intensive Care Unit, Hospital Insular, Plaza Dr. Pasteur s/n. Las Palmas de Gran Canaria, 35016, Spain
5Intensive Care Unit, Hospital Universitario Dr. Negrín, Barranco de la Ballena s/n. Las Palmas de Gran Canaria, 35010, Spain
6Intensive Care Unit, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez no. 17-19, Valencia, 46004, Spain
7Atherosclerosis Research Laboratory, CIMA-University of Navarra, Avda Pío XII no. 55, Pamplona, 31008, Spain
8Research Unit, Hospital Universitario de Canarias, Ofra, s/n. La Laguna, 38320, Santa Cruz de Tenerife, Spain
9Laboratory Deparment, Hospital Universitario de Canarias, Ofra, s/n. La Laguna, 38320, Santa Cruz de Tenerife, Spain
10Laboratory Department, Hospital San Jorge de Huesca, Avenida Martínez de Velasco no. 36, Huesca, 22004, Spain
11Microbiology Department, Hospital Universitario de Canarias, Ofra, s/n. La Laguna, 38320, Santa Cruz de Tenerife, Spain
Corresponding author: Leonardo Lorente, lorentemartin@msn.com
Received: 1 Jun 2009 Revisions requested: 3 Jul 2009 Revisions received: 1 Sep 2009 Accepted: 2 Oct 2009 Published: 2 Oct 2009
Critical Care 2009, 13:R158 (doi:10.1186/cc8115)
This article is online at: http://ccforum.com/content/13/5/R158
© 2009 Lorente et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Matrix metalloproteinases (MMPs) play a role in
infectious diseases through extracellular matrix (ECM)
degradation, which favors the migration of immune cells from the
bloodstream to sites of inflammation. Although higher levels of
MMP-9 and tissue inhibitor of matrix metalloproteinases-1
(TIMP-1) have been found in small series of patients with sepsis,
MMP-10 levels have not been studied in this setting. The
objective of this study was to determine the predictive value of
MMP-9, MMP-10, and TIMP-1 on clinical severity and mortality
in a large series of patients with severe sepsis.
Methods This was a multicenter, observational, and prospective
study carried out in six Spanish Intensive Care Units. We
included 192 (125 surviving and 67 nonsurviving) patients with
severe sepsis and 50 age- and sex-matched healthy controls in
the study. Serum levels of MMP-9, MMP-10, TIMP-1, tumor
necrosis factor (TNF)-alpha, and interleukin (IL)-10 were
measured in patients with severe sepsis at the time of diagnosis
and in healthy controls.
Results Sepsis patients had higher levels of MMP-10 and TIMP-
1, higher MMP-10/TIMP-1 ratios, and lower MMP-9/TIMP-1
ratios than did healthy controls (P < 0.001). An association was
found between MMP-9, MMP-10, TIMP-1, and MMP-9/TIMP-1
ratios and parameters of sepsis severity, assessed by the SOFA
score, the APACHE-II score, lactic acid, platelet count, and
markers of coagulopathy. Nonsurviving sepsis patients had
lower levels of MMP-9 (P = 0.037), higher levels of TIMP-1 (P <
0.001), lower MMP-9/TIMP-1 ratio (P = 0.003), higher levels of
IL-10 (P < 0.001), and lower TNF-α/IL-10 ratio than did
surviving patients. An association was found between MMP-9,
MMP-10, and TIMP-1 levels, and TNF-α and IL-10 levels. The
risk of death in sepsis patients with TIMP-1 values greater than
531 ng/ml was 80% higher than that in patients with lower
values (RR = 1.80; 95% CI = 1.13 to 2.87;P = 0.01; sensitivity
= 0.73; specificity = 0.45).Page 1 of 9
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severe sepsis (to our knowledge, the largest series reporting
data about MMP levels in sepsis) are that reduced MMP-9/
TIMP-1 ratios and increased MMP-10 levels may be of great
pathophysiologic significance in terms of severity and mortality,
and that TIMP-1 levels may represent a biomarker to predict the
clinical outcome of patients with sepsis.
Introduction
Matrix metalloproteinases (MMPs) are a family of zinc-contain-
ing endoproteinases implicated in degradation and remodel-
ling of the extracellular matrix (ECM). They can be classified
broadly by substrate specificity into collagenases (MMP-1, -8,
and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -
10, -11), elastases (MMP-7 and -12), and membrane-type
(MT-MMPs, MMP-14, -15, -16, and -17). MMPs have a role in
normal physiologic functions such as the menstrual cycle, mor-
phogenesis, tissue remodelling and angiogenesis, and in dis-
eases with abnormal ECM turnover, such as arthritis, tumor
invasion, aneurysm formation, and atherosclerosis [1,2]. Reg-
ulation of MMP activity is carried out by specific tissue inhibi-
tors of matrix metalloproteinases (TIMPs) [1,2].
MMPs play a role in infectious diseases when the host immune
system is challenged by an invading organism, facilitating the
recruitment of leukocytes from the bloodstream; these migrate
to the site of infection for eradication of the pathogen (by pro-
teolysis of the basement membrane) and for modulating the
inflammatory response [3]. The action of MMPs and TIMPs
has been reported in the coagulation/fibrinolytic system [4-6];
thus the MMP/TIMP system may play a role in the coagulation/
fibrinolytic response to sepsis.
Small clinical studies (with fewer than 40 patients) have
shown higher plasma levels of MMP-9 [7-13] and TIMP-1
[9,11,13] in sepsis patients as compared with those observed
in controls, and higher levels of TIMP-1 [11] or MMP-9 [12] in
nonsurviving than in surviving patients. However, no correla-
tion between MMP levels and different indicators of severity in
sepsis were reported, except for MMP-9 and Acute Physiology
and Chronic Health Evaluation (APACHE)-II score [12]. It was
recently suggested that MMP-10 plays a role in the develop-
ment of atherosclerosis [14-16], and in vitro studies found
increased MMP-10 levels after infective stimulation of human
[17] and mice [18] airway epithelial cells; however, no studies
assessing MMP-10 levels have been reported in sepsis.
Thus, the objective of this study was to determine the influence
of the circulating levels of MMP-9, MMP-10, and TIMP-1 on
the severity and mortality of patients with sepsis in a large
cohort.
Materials and methods
Design and subjects
A multicenter, observational, prospective study was carried
out in six Spanish Intensive Care Units. The study was
approved by the Institutional Review Boards of the six hospi-
tals, and informed consent from the patients or from the family
members was obtained. In total, 192 patients with severe sep-
sis (mean age, 58 years; 66% men) and 50 age- and sex-
matched healthy controls (mean age, 55 years; 73% men)
were included.
The diagnosis of sepsis and severe sepsis was established
according to the International Sepsis Definitions Conference
[19]. Sepsis was defined as a documented or suspected
infection (defined as a pathologic process induced by a micro-
organism) and some of the following parameters:
One
General parameters: fever (core temperature higher than
38.3°C), hypothermia (core temperature lower than 36.0°C),
tachycardia (heart rate greater than 90 beats/min), tachypnea
(respiratory rate higher than 30 breaths/min), altered mental
status, significant edema or positive fluid balance (higher than
20 ml/kg over a 24-hour period), hyperglycemia (plasma glu-
cose higher than 110 mg/dl) in the absence of diabetes.
Two
Inflammatory parameters: leukocytosis (white blood cell count
higher than 12,000/mm3), leukopenia (white blood cell count
lower than 4,000 mm3), normal white blood cell count with a
percentage of immature forms higher than 10%, plasma C-
reactive protein more than 2 standard deviations above the
normal value, plasma procalcitonina more than 2 standard
deviations above the normal value.
Three
Hemodynamic parameters: arterial hypotension (systolic
blood pressure lower than 90 mm Hg, mean arterial blood
pressure lower than 70 mm Hg, or decrease of systolic blood
pressure from the baseline to higher than 40 mm Hg), mixed
venous oxygen saturation higher than 70%, cardiac index
higher than 3.5 l/min/m2.
Four
Organ dysfunction: arterial hypoxemia (pressure of arterial oxy-
gen/fraction inspired oxygen (PaO2/FIO2) ratio <300), acute
oliguria (urine output less than 0.5 ml/kg/h for at least 2 hours),
creatinine increase of 0.5 mg/dl or more, coagulation abnor-
malities defined as international normalized ratio (INR) more
than 1.5 or activated partial thromboplastin time (aPTT) more
than 60 seconds, ileus (absent bowel sounds), thrombocyto-Page 2 of 9
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(plasma total bilirubin more than 4 mg/dl).
Five
Tissue perfusion parameters: hyperlactatemia (more than 3
mmol/l), decreased capillary refill or mottling.
Severe sepsis was defined as sepsis complicated by organ
dysfunction.
Exclusion criteria were age younger than 18 years, pregnancy,
lactation, human immunodeficiency virus (HIV), white blood
cell count less than 1,000/μl, solid or hematologic tumor, or
immunosuppressive, steroid, or radiation therapy.
Variables recorded
The following variables were recorded for each patient: sex,
age, diabetes mellitus, chronic obstructive pulmonary disease
(COPD), site of infection, creatinine, leukocytes, lactic acid,
platelets, INR, aPTT, and the Acute Physiology and Chronic
Health Evaluation II (APACHE II) score [20], Sepsis-related
Organ Failure Assessment [SOFA] score [21], and ICU mor-
tality (defined as the death of the patient in the ICU).
Blood samples were collected from 192 patients with severe
sepsis at the time of the diagnosis (within the first 2 hours after
the diagnosis of severe sepsis) and from 50 age- and sex-
matched controls.
MMP-9, MMP-10, TIMP-1, TNF-α, and IL-10 assays
Serum separator tubes (SSTs) were used to determine MMPs
and TIMP-1 concentration in serum. Venous blood samples
were taken and centrifuged within 30 minutes at 1,000 g for
15 minutes, and the serum was removed and frozen at -80°C
until measurement. MMP-9, MMP-10, and TIMP-1 were
assayed with specific ELISA (Quantikine, R&D Systems,
Abingdon, UK) according to the manufacturer's instructions
with a serum dilution of 1:80, 1:2, and 1:100, respectively. The
interassay coefficients of variation (CV) were less than 8% (n
= 20), and the detection limits for the assays were 0.31 ng/ml,
78.1 pg/ml, and 0.15 ng/ml. TNF-α and IL-10 serum levels
were measured with a solid-phase, chemiluminescence immu-
nometrics assays kit (Immulite, Siemens Healthcare Diagnos-
tics Products, Llanberis, UK); and the interassay coefficients
of variation (CVs) were less than 6.5% (n = 20) and less than
9.9% (n = 40), and the detection limits for the assays were 1.7
pg/ml and 1 pg/ml, respectively.
Statistical methods
Continuous variables are reported as medians and interquar-
tile ranges. Categoric variables are reported as frequencies
and percentages. Comparisons of continuous variables
between groups were carried out by using the Wilcoxon-
Mann-Whitney test. Comparisons between groups on cate-
goric variables were carried out with the χ2 (chi-square) test.
The association between continuous variables was carried out
by using the Spearman rank correlation coefficient or the
Spearman rho coefficient. Receiver operation characteristic
(ROC) curves were constructed to represent the goodness-
of-fit of TIMP-1, lactic acid, and SOFA scores as criterion var-
iables and mortality as the response variable. Relative risk and
95% confidence intervals were calculated as measurements
of the clinical impact of the predictor variables. A P value of
less than 0.05 was considered statistically significant. Statisti-
cal analyses were performed with SPSS 17.0 (SPSS Inc., Chi-
cago, IL, USA) and NCSS 2000 (Kaysville, Utah, USA).
Results
Baseline clinical characteristics and the median values (25th to
75th percentiles) of MMP-9, MMP-10, and TIMP-1 in sepsis
patients and controls are shown in Table 1. No significant dif-
ferences were found between 192 sepsis patients and 50
controls in terms of age and sex. Higher serum levels of MMP-
10 (P < 0.001) and TIMP-1 (P < 0.001), and nonsignificantly
Table 1
Comparison of MMP-9, MMP-10, and TIMP-1 serum levels between sepsis patients and controls (median and 25th to 75th percentiles 
are shown)
Controls
(n = 50)
Sepsis
patients
(n = 192)
P
Gender female: number (%) 13 (26.0) 64 (33.3) 0.11
Age (years) 57 (50-63) 60 (49-70) 0.39
MMP-9 (ng/ml) 498 (350-735) 676 (308-1,164) 0.07
TIMP-1 (ng/ml) 226 (213-241) 618 (445-831) <0.001
MMP-10 (pg/ml) 466 (288-614) 1,880 (1,217-3,285) <0.001
MMP-9/TIMP-1 (ratio) 2.19 (1.57-3.01) 1.16 (0.49-2.24) <0.001
MMP-10/TIMP-1 (ratio) 2.07 (1.17-2.84) 3.09 (2.08-5.06) <0.001
MMP = Matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase.Page 3 of 9
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compared with controls. The MMP-9/TIMP-1 ratio was mark-
edly reduced in patients (P < 0.001), whereas the MMP-10/
TIMP-1 ratio was significantly increased (P < 0.001).
Comparisons of demographic and clinical parameters
between nonsurviving (n = 67) and surviving sepsis patients (n
= 125) are shown in Table 2. Whereas no differences were
observed regarding age, sex, COPD, site of infection, and leu-
kocytes; the nonsurviving sepsis patients showed a higher
incidence of diabetes mellitus, higher levels of lactic acid and
creatinine, prolonged aPTT, and reduced platelet count,
together with increased SOFA and APACHE-II scores. More-
over, higher levels of TIMP-1 (P < 0.001), reduced MMP-9 (P
= 0.037), and a nonsignificant increase of MMP-10 were
found in nonsurviving as compared with surviving sepsis
patients (Table 3). The ratio between MMP-9 and TIMP-1 was
decreased in nonsurviving patients, whereas no differences in
the MMP-10/TIMP-1 ratio were found. Finally, no significant
differences in the levels of MMPs and TIMP-1 in relation to the
presence of diabetes were found.
Correlations between MMPs, TIMP-1, and severity of sepsis
parameters are shown in Table 4. MMP-9 negatively corre-
lated with SOFA, lactic acid, and coagulopathy markers (all P
< 0.001) and positively with platelet count (P < 0.001). In con-
trast, TIMP-1 positively correlated with SOFA, lactic acid, and
markers of coagulopathy (all p < 0.001). MMP-10 also corre-
lated positively with SOFA and lactic acid (P < 0.001) and
negatively with platelets (P < 0.001). Interestingly, although
the MMP-9/TIMP-1 ratio showed significant correlations with
all parameters of severity, no differences were found for the
MMP-10/TIMP-1 ratio.
Table 2
Demographic and clinical parameters of surviving and nonsurviving sepsis patients (median and 25th to 75th percentiles or 
percentage when indicated are shown)
Survivors
(n = 125)
Nonsurvivors
(n = 67)
P
Gender female: number (%) 40 (31.2) 24 (37.5) 0.27
Age: median years (percentile 25-75) 56 (47-69) 62 (52-71) 0.15
Diabetes mellitas: number (%) 25 (19.8) 24 (37.5) 0.02
COPD: number (%) 17 (13.5) 10 (15.6) 0.67
Site of infection 0.82
• Respiratory: number (%) 67 (53.2) 38 (59.4)
• Abdominal: number (%) 28 (22.2) 13 (20.3)
• Other sites: number (%) 31(24.6) 13 (20.3)
APACHE-II score: median (percentile 25-75) 19 (14-22) 24 (18-29) <0.001
Creatinine (mg/dl): median (percentile 25-75) 1.2 (0.80-2.05) 1.6 (0.9-2.8) 0.02
Leukocytes: median/mm3 (percentile 25-75) 14,600 (8,900-20,050) 15,200 (9,050-20,625) 0.39
Lactic acid: median mmol/L (percentile 25-75) 2,00 (1.20-3.70) 3.95 (1.47-6.55) <0.001
Platelets: median/mm3 (percentile 25-75) 210,000 (127,000-273,000) 139,000 (63,000-218,250) <0.001
INR: median (percentile 25-75) 1.27 (1.10-1.50) 1.42 (1.10-1.66) 0.17
aPTT: median seconds (percentile 25-75) 30 (26-39) 39 (30-47) <0.001
SOFA store: median (percentile 25-75) 9 (7-11) 12 (9-14) <0.001
• Respiratory: median (percentile 25-75) 3 (2-3) 3 (2-3) 0.07
• Hematologic: median (percentile 25-75) 0 (0-1) 1 (0-2) <0.001
• Hepatic: median (percentile 25-75) 0 (0-1) 0 (0-1) 0.75
• Cardiovascular: median (percentile 25-75) 4 (4-4) 4 (4-4) 0.006
• Neurologic: median (percentile 25-75) 0 (0-1) 0 (0-3) 0.22
• Renal: median (percentile 25-75) 0 (0-2) 2 (0-4) <0.001
APACHE II = Acute Physiology and Chronic Health Evaluation; aPTT = activated partial thromboplastin time; COPD = chronic obstructive 
pulmonary disease; INR = international normalized ratio; SOFA = Sepsis-related Organ-failure Assessment score.Page 4 of 9
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uring TNF-α and IL-10, to elucidate whether it could account
for differences observed in MMPs and TIMP-1. Nonsurviving
sepsis patients exhibited much higher levels of IL-10 than did
the survivors, whereas no differences could be observed in
TNF-α (Table 3). Moreover, IL-10 positively correlated with
TIMP-1 and MMP-10, whereas a negative association could
be observed for MMP-9 (Table 5).
We performed an ROC analysis to determine whether the
parameters analyzed could be used to predict outcomes in
sepsis patients. Figure 1 shows the ROC analysis for mortality
estimation. The areas under the curves as predictors of mortal-
ity were the following: TIMP-1 (AUC = 0.68; 95% CI = 0.59
to 0.76; P < 0.001), lactic acid (AUC = 0.67; 95% CI = 0.58
to 0.75; P < 0.001), and SOFA score (AUC = 0.71; 95% CI
= 0.64 to 0.79; P < 0.001). The optimal cut-off for each pre-
dictor was TIMP-1 >531 ng/ml (RR = 1.80; 95% CI = 1.13 to
2.87;P = 0.01; sensitivity = 0.73; specificity = 0.45), lactic
acid >3.1 mmol/L (RR = 2.13; 95% CI = 1.44 to 3.16;P
<0.001; sensitivity = 0.55; specificity= 0.75), and SOFA
score >8 points (RR = 3.12; 95% CI = 1.52 to 6.38;P
<0.001; sensitivity = 0.82; specificity = 0.45).
Discussion
To our knowledge, this study includes the largest series
reporting data on MMP levels in sepsis. The most relevant find-
ings were the following: (a) higher serum levels of MMP-10
and TIMP-1, and nonsignificantly higher MMP-9 levels in sep-
sis patients than in healthy controls; (b) a significant correla-
Table 3
Comparison of MMP-9, MMP-10, TIMP-1, TNF-α, and IL-10 serum levels between surviving and nonsurviving sepsis patients 
(median and 25th to 75th percentiles are shown)
Survivors
(n = 125)
Nonsurvivors
(n = 67)
P
MMP-9: median ng/ml (percentile 25-75) 784 (371-1222) 554 (240-1044) 0.037
TIMP-1: median ng/ml (percentile 25-75) 573 (422-724) 797 (499-1,012) <0.001
MMP-10: median pg/ml (percentile 25-75) 1,850 (1,187-2,956) 2,284 (1,262-4,329) 0.09
MMP-9/TIMP-1 ratio: median (percentile 25-75) 1.39 (0.63-2.42) 0.82 (0.28-1.66) 0.003
MMP-10/TIMP-1 ratio: median (percentile 25-75) 3.12 (2.14-5.06) 2.97 (1.72-5.21) 0.46
TNF-α: median pg/ml (percentile 25-75) 30 (19-51) 34 (18-70) 0.38
IL-10: median pg/ml (percentile 25-75) 10 (5-37) 36 (9-103) <0.001
TNF-α/IL-10 ratio: median (percentile 25-75) 2.49 (1.39-3.92) 1.20 (0.47-2.38) <0.001
IL = interleukin; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase; TNF = tumor necrosis factor.
Table 4
Correlation between MMP-9, MMP-10, and TIMP-1 serum levels with lactic acid, SOFA, platelets, and coagulation markers in sepsis 
patients
Lactic acid
(mmol/L)
APACHE-II
(points)
SOFA
(points)
Platelet count
(platelets/mm3)
aPTT
(seconds)
INR
(ratio)
MMP-9: ng/ml Rho = -0.31 Rho = -0.34 Rho = -0.37 Rho = 0.48 Rho = -0.28 Rho = -0.28
P < 0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.001 P = 0.001
TIMP-1: ng/ml Rho = 0.51 Rho = 0.38 Rho = 0.42 Rho = -0.24 Rho = 0.29 Rho = 0.41
P < 0.001 P < 0.001 P < 0.001 P = 0.001 P < 0.001 P < 0.001
MMP-10: pg/ml Rho = 0.29 Rho = 0.33 Rho = 0.36 Rho = -0.24 Rho = 0.13 Rho = 0.22
P < 0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.13 P = 0.008
MMP-9/TIMP-1 ratio Rho = -0.45 Rho = -0.42 Rho = -0.48 Rho = 0.49 Rho = -0.38 Rho = -0.4
P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
MMP-10/TIMP-1 ratio Rho = 0.01 Rho = 0.11 Rho = 0.04 Rho = -0.08 Rho = -0.09 Rho = -0.03
P = 0.95 P = 0.13 P = 0.77 P = 0.30 P = 0.29 P = 0.72
aPTT = Activated partial thromboplastin time; INR = international normalized ratio; MMP = matrix metalloproteinase; rho = Spearman's rank 
correlation coefficient; SOFA = Sepsis-related Organ-Failure Assessment score; TIMP = tissue inhibitor of matrix metalloproteinase.Page 5 of 9
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of severity in sepsis, including biomarkers of coagulation, lac-
tic acid, APACHE-II, and SOFA scores; and (c) the nonsurviv-
ing sepsis patients had higher TIMP-1 levels, lower MMP-9/
TIMP-1 ratios, and nonsignificantly higher MMP-10 levels than
did surviving patients. Taken together, these results indicate
that an alteration in the MMP-9/TIMP-1 ratio and MMP-10 lev-
els may be of great pathophysiologic significance in sepsis
patients.
Previous studies with small sample sizes (fewer than 40
patients) have shown higher levels of MMP-9 [7-13] and TIMP-
1 [9,11,13] in sepsis patients than in controls. In our larger
study, we found significantly higher levels of TIMP-1, reduced
MMP-9/TIMP-1 ratios, and nonsignificantly higher MMP-9 lev-
els in sepsis patients than in healthy controls. The small
number of healthy controls may have contributed to the
absence of significant differences in MMP-9 levels between
the sepsis patients and these healthy controls. In addition, we
report for the first time that sepsis patients have higher levels
of MMP-10 than do controls.
Interestingly, we observed a significant correlation between
MMP-10 and TIMP-1 and several markers of sepsis severity,
such as SOFA and APACHE-II scores, lactic acid, and mark-
ers of coagulopathy; whereas MMP-9 negatively correlated
with all the aforementioned parameters of sepsis severity.
Therefore, besides the already known higher mortality rate in
sepsis patients with increased lactic acid levels [22,23] and
SOFA score [24], our results suggest that alterations in the
MMP-9/TIMP-1 ratio and MMP-10 levels are associated with
the severity of sepsis. However, we must note the apparent
contradiction with a previous report of positive correlation
between MMP-9 and APACHE-II score in sepsis patients [12].
After analyzing MMPs and TIMP-1 levels in relation to mortality,
in our study, we found higher plasma levels of TIMP-1 and
lower levels of MMP-9 in nonsurviving sepsis patients.
Whereas higher levels of TIMP-1 were reported previously in
nonsurviving patients [11], conflicting results regard MMP-9
[11,12]. Nakamura [12] observed higher levels of MMP-9,
whereas Hoffman [11] found no differences in MMP-9 in non-
surviving sepsis patients. The reduced size of previous stud-
ies, particularly the group of nonsurvivors, could be affecting
their statistical power and thus account for the apparent con-
tradictory results. Although MMP-9 is secreted mainly by leu-
kocytes [3], the observed differences cannot be explained by
the leukocyte numbers, which were similar in both nonsurviv-
ing and surviving patients. Because TNF-α and IL-10 have
been shown to modulate MMP-9 and TIMP-1 expression, we
explored circulating levels of these cytokines. Although similar
TNF-α levels were found in both groups, the augmented IL-10
observed in nonsurvivors could be responsible for reduced
Table 5
Correlation between MMP-9, MMP-10, and TIMP-1 with TNF-α and IL-10 serum levels
TNF-α (pg/ml) IL-10 (pg/ml) TNF-α/IL-10 ratio
MMP-9: ng/ml rho = -0.25 rho = -0.38 rho = 0.33
p = 0.001 p < 0.001 p < 0.001
TIMP-1: ng/ml rho = 0.56 rho = 0.50 rho = -0.26
p < 0.001 p < 0.001 p = 0.001
MMP-10: pg/ml rho = 0.35 rho = 0.30 rho = -0.16
p < 0.001 p < 0.001 p = 0.04
SOFA = Sepsis-related Organ Failure Assessment score; aPTT = Activated partial thromboplastin time; INR = International normalized ratio; 
MMP = Matrix metalloproteinase; TIMP = Iissue inhibitor of matrix metalloproteinase; IL = interleukin; rho = Spearman's rank correlation 
coefficient.
Figure 1
Receiver operation characteristic analysis using TIMP-1, lactic acid, and SOFA score as predictor  of mortality
and SOFA score as predictors of mortality.  The areas under the curves 
(AUC) for each predictor of mortality were the following: tissue inhibitor 
of matrix metalloproteinase (TIMP)-1 (AUC = 0.68; 95% CI = 0.59 to 
0.76; P < 0.001), lactic acid (AUC = 0.67; 95% CI = 0.58 to 0.75; P < 
0.001) and Sepsis-related Organ Failure Assessment score (SOFA) 
score (AUC = 0.71; 95% CI = 0.64 to 0.79; P < 0.001).Page 6 of 9
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patients, because this anti-inflammatory cytokine has been
shown to induce TIMP-1 and reduce MMP-9 expression in
endothelium/monocyte cocultures [25].
When we performed ROC curve analysis to represent the
goodness-of-fit of studied variables for predicting mortality, we
found that TIMP-1 was a good predictor of mortality, com-
pared with two well-established indicators for the same out-
come: lactic acid levels and SOFA score. This result confirms
previous observations from Hoffman et al. [11], showing that
TIMP-1 and APACHE-II were predictors for outcome in 37
patients and reporting a relative risk of 4.5 for the cut-off point
of TIMP-1 chosen, but with a large confidence interval (1.14 to
17.6). One strength of the present study is the large sample
size that allowed us to increase the accuracy of the estimated
parameters. In our study of 192 patients, the cut-off point pre-
sented a narrower confidence interval (relative risk, 1.8; 95%
CI, 1.13 to 2.87). The TIMP-1 levels found in our study are
lower, as described in previous studies, probably because of
the use of different commercial kits in the TIMP-1 assay.
According to the package insert of the kit that we used, mean
TIMP-1 serum levels drawn from 60 apparently healthy volun-
teers were 190 ng/ml. In our study, median TIMP-1 serum lev-
els in healthy controls were 226 ng/ml. In the study by
Hoffmann et al. [11], the mean plasma levels of TIMP-1 in 37
healthy controls were 742 ± 34 ng/ml by using other commer-
cial ELISA kits to determine TIMP-1 in plasma (Biotrak; Amer-
sham Biosciences, Freiburg, Germany). Another potential
explanation could be the existence of differences in the patient
characteristics of each series; however, the APACHE-II score
was not different from that in the previous study published by
Hoffmann et al. In our study, the median APACHE-II scores
were 19 and 24 in surviving and nonsurviving patients, respec-
tively; and in the study by Hoffmann et al. [11], the mean
APACHE-II scores were 14 and 23 in surviving and nonsurviv-
ing patients, respectively.
The role of MMPs/TIMPs in sepsis remains unclear; but the
results of some studies indicate that MMPs play a certain role
in the recruitment of leukocytes from the bloodstream to the
site of infection [26-28], and in the inflammation [29-37] and
coagulation/fibrinolysis response [38-41]. The migration of
immune cells from the bloodstream to sites of inflammation
requires MMP-mediated proteolysis of the basement mem-
brane, as reported in vitro [26] and in animal models [27,28].
MMPs may play a role in the inflammatory process because
they modulate [29-32] and are modulated by cytokines [33-
37]. MMPs have been found to promote the release of tumor
necrosis factor (TNF)-α [29], to activate pro-interleukin (pro-
IL)-1β [30], to cleave the activated form of IL-1β [31], and to
convert IL-8 into a fragment 10 times more active than the par-
ent molecule [32]. MMPs are secreted in response to
cytokines such as TNF-α [33] and IL-1β [34] and are down-
regulated by diverse cytokines including interferon (IFN)-γ
[35], IL-4 [36], and IL-10 [37]. Steroids, progesterone, and
retinoids also downregulate MMPs [42]. Animal models have
shown that endotoxinemia leads to the release of MMP-9 and
endotoxin-induced shock in mice and that MMP-9-deficient
mice were resistant to endotoxin-induced shock [43]. The rela-
tion between coagulation and inflammation in sepsis is already
known [44-46]; and it is possible that MMPs/TIMPs may also
play a role in the coagulation/fibrinolysis response in sepsis, as
suggested by studies showing that MMP-9 inhibits platelet
aggregation [39,40] and a positive correlation between TIMP-
1 and PAI-1 [38].
All this indicates that sepsis is a complex clinical process with
an interconnection between inflammatory and coagulation
response; the inflammatory mediators activate coagulation
and, conversely, intravascular coagulation induces an inflam-
matory response. We believe that the lower MMP-9/TIMP-1
ratio and higher MMP-10 levels in nonsurvivors than in surviv-
ing patients found in our study may be associated with a
higher inflammatory and prothrombotic/antifibrinolytic state,
responsible for the capillary thrombosis, multiple organ dys-
function, and death.
From a therapeutic perspective, the development of modula-
tors of MMP/TIMP activity could be used as a new class of
drugs for the treatment of severe sepsis, as suggested by the
beneficial effect of targeting MMPs with the administration of
sub-inhibitory doses of tetracycline reported in animal models
of sepsis [47,48].
Whereas the strength of our study was the relatively large
sample size that allowed us to increase the accuracy of the
analyzed parameters in relation to previous studies [11,12],
some limitations should be recognized. No analysis of MMP-9,
MMP-10, and TIMP-1 during follow-up was performed; thus,
we were unable to establish the time course of MMP/TIMP
activity in the surviving patients compared with the nonsurvi-
vors; therefore, additional prospective studies are required.
Measuring other inflammatory cytokines, such as IL-6, would
be desirable to evaluate better the relation between MMP/
TIMP activity and inflammatory response in this set of patients;
however, the number of analytic determinations per patient in
our study was limited by available economic support. Higher
dispersion in variables measured in the sepsis group led us to
increase its sample size, thus constraining the dimension of
the control group within the available funding for this study.
The relatively small sample size of the control group may have
contributed to the absence of significant differences in MMP-
9 levels between controls and sepsis patients. Including other
control groups, such as critically ill but nonsepsis patients,
would be desirable for future studies to elucidate whether
observed changes are specific for the septic setting.Page 7 of 9
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Critical Care    Vol 13 No 5    Lorente et al.Conclusions
The novel findings of our study on severe sepsis patients are
that reduced MMP-9/TIMP-1 ratio and increased MMP-10 lev-
els may be of great pathophysiologic significance in terms of
severity and mortality; and that TIMP-1 levels may represent a
biomarker to predict the clinical outcome of sepsis patients.
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